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Summary Pituitary tumours develop at a high frequency in p27-knockout mice and retinoblastoma gene-knockout mice, which suggests that
cell cycle regulatory genes, such as cyclin-dependent kinase inhibitor genes, are involved in the tumorigenesis of pituitary adenoma. Analysis
of p21 and p27 gene abnormalities in human pituitary adenoma was performed in 28 pituitary adenomas by polymerase chain
reaction-single-strand conformational polymorphism. No point mutations were detected in these genes. As no abnormalities of the p21 and
p27genes were observed, and if these genes are indeed inactivated, it is likely to be via transcriptional or translational defects.
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Control ofcell proliferation is managed by a series ofcheckpoints
that regulate cell cycle progression. In recent years, molecular
analysis has revealed various abnormalities in the regulatory genes
(MacLachlan et al, 1995; Pines, 1995). Retinoblastoma protein
(pRb) is a critical target of these cell cycle regulatory genes to
promote progression through theG, phase ofthe cell cycle.
Sequential activation ofcyclin, cyclin-dependent kinase (CDK)
complexes is thought to be responsible for orderly transitions
through the cell cycle (MacLachlan et al, 1995; Pines, 1995). The
abnormal activation of CDK activity leads to underphosphoryla-
tion ofpRb and may underlie the uncontrolled growth that charac-
terizes neoplasms. The family of low-molecular-weight CDK
inhibitors, which includesp15, p16, p2] andp27 gene products, is
essential in arresting cell cycle progression (MacLachlan et al,
1995; Pines, 1995).
The high incidence of spontaneous pituitary adenoma (almost
100%) that develops in heterozygous Rb-knockout mice (Jacks et
al, 1992; Hu et al, 1994) implicates the Rb pathway in pituitary
tumorigenesis, although mutation of the Rb gene itself is infre-
quent in human pituitary adenoma (Cryns et al, 1993; Ikeda et al,
1995). Recently, the homozygous p27-knockout mouse was found
to develop a high incidence ofpituitary adenoma (Fero et al, 1996;
Kiyokawa et al, 1996; Nakayama et al, 1996). Both the Rb muta-
tion and the p27-'- mice developed morphologically similar
tumours originating in the pars intermedia of the pituitary gland.
Therefore, thep27 and Rb functions are thought to be in the same
regulatory pathway and are important in the tumorigenesis of
pituitary adenoma in mice.
The present study investigated genetic changes in p21 and p27
in human pituitary adenomas using polymerase chain reaction
(PCR)-single-strand conformational polymorphism (SSCP)
analysis and direct sequencing.
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MATERIALS AND METHODS
Human tissue samples
Twenty-eight samples of pituitary adenoma were obtained at
surgery. The histological subtypes were 16 cases of gonadotroph
adenoma, five cases of null cell adenoma, four cases of pluri-
hormonal adenoma and three cases of silent corticotroph cell
adenoma (Table 1). The resected specimens were frozen immedi-
ately in liquid nitrogen and stored at -70°C until analysis.
DNA isolation
Only pituitary tumour tissues were removed at operation because
most of them are soft and easily suckable, in contrast to normal
pituitary tissue which is hard to remove by suction or curettage.
Adenoma tissues are usually soft because the tissue contains little
supportive tissue, such as fibrous stroma and blood vessels; this
allowed easy digestion with 1% sodium dodecyl sulphate and
proteinase K overnight at 50°C. DNA was extracted with
phenol-chloroform, then precipitated with cold ethanol overnight
at -20°C. The precipitate was separated by centrifugation. The
pellets were dried and resuspended in TE buffer solution (10 mM
Tris, 1 mm EDTA; pH 8.0) for storage at 4°C until analysis.
RNA isolation
mRNA was isolated from tissues using the QuickPrepR Micro
mRNA purification kit, which combines the disruptive and protec-
tive properties of guanidinium thiocyanate with the speed and
selectivity of oligo(dT)-cellulose chromatography in a spun-
column format (Pharmacia Biotech, Tokyo, Japan).
Reverse transcription (RT)-PCR analysis of p21
Full-length first-strand cDNA was obtained by mixing mRNA
template (33 Iil) and First-Strand Reaction Mix (T-primed first-
strand kit; Pharmacia Biotech). The first-strand cDNA was ampli-
fied in a 100 gl mixture containing 6 jul ofthe first-strand reaction,
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Table 1 Clinicopathological features of 28 patients with pituitary adenoma
Case Age Sex Histology
no. (years)
1 27 F Gonadotroph adenoma
2 37 M Null Cell adenoma
3 42 F Silent ACTH adenoma
4 68 M Gonadotroph adenoma
5 44 F Plurihormonal adenoma
6 47 F Silent ACTH adenoma
7 68 M Gonadotroph adenoma
8 54 F Plurihormonal adenoma
9 75 F Null cell adenoma
10 61 F Gonadotroph adenoma
11 45 M Gonadotroph adenoma
12 66 M Gonadotroph adenoma
13 67 F Gonadotroph adenoma
14 50 M Gonadotroph adenoma
15 46 M Gonadotroph adenoma
16 56 F Gonadotroph adenoma
17 50 M Gonadotroph adenoma
18 42 M Null cell adenoma
19 46 M Null cell adenoma
20 43 F Silent ACTH adenoma
21 70 M Gonadotroph adenoma
22 31 M Plurihormonal adenoma
23 72 F Gonadotroph adenoma
24 52 M Plurihormonal adenoma
25 41 M Gonadotroph adenoma
26 68 F Gonadotroph adenoma
27 47 F Null cell adenoma
28 23 F Gonadotroph adenoma
ACTH, adrenocorticotrophic hormone.
10 ,l of PCR buffer (500 mm potassium chloride, 100 mM Tris,
15 mm magnesium chloride, 0.01% gelatin; pH 8.3), 1 pl of 20
mM dNTP mixture, 40 pmol of each primer and 2.5 units of Taq
DNA polymerase (Takara, Ootsu, Japan). The primers used for the
amplification of the full length of p2] were 5'-CACTCAGAG-
GAGGCGCCATGTCA-3' and 5'-TTCCAGGACTGCAGGCTFT-
CCT-3'. The control study of the RT-PCR reaction used rabbit
globulin (550 bp) obtained by mixing mRNA template and control
mixture (Pharmacia Biotech).
Table 2 Sequence of primers
Primer Sequence
p21AF 5'-CACTCAGAGGAGGCGCCATGTCA-3'
p21AR 5'-TCGAAGTTCCATCGCTCACG-3'
p21 BF 5'-ACTGTGATGCGCTAATGGCG-3'
p21 BR 5'-ATGGTCTTCCTCTGCTGT-3'
p21 CF 5'-ACCTCACCTGCTCTGCTGCA-3'
p21CR 5'-TTCCAGGACTGCAGGCTTCCT-3'
p27E1AF 5'-TGCAGACCCGGGAGAAAGATGT-3'
p27E1AR 5'-ATCGAAATTCCACTTGCGCT-3'
p27E1BF 5'-AGAGACATGGAAGAGG-3'
p27E1 BR 5'-TGCCATCCTGGCTCTCCT-3'
p27E1CF 5'-AAGGGCAGCTTGCCCGAGTTCTA-3'
p27E1CR 5'-GTTGGGAAAGGGCATTACCGT-3'
p27E2F 5'-TCCCCTGCGCTTAGATTCTTC-3'
p27E2R 5'-TGATCAACCCACCGAGCTGT-3'
PCR-SSCP analysis
PCR primer pairs for the amplification of the cDNA ofp2] and
genomic DNA of p27 were synthesized by Japan Genetic
Research (Sendai, Japan) (Figure 1 and Table 2). PCR fragments
were generated from 3 to 6,l of the amplified cDNA solution in
100 pl ofa mixture of200 ,M dTTP, 200gM dATP, 200gM dGTP,
20 ,M dCTP, 1.0-2.0 mm magnesium chloride, 20 pmol of each
primer, 20 mm Tris (pH 8.4 or pH 8.6), 50 mm potassium chloride,
2.5 units of Taq DNA polymerase and 0.1 pCi of [a-32P]dCTP.
The magnesium chloride concentration and pH of the amplifica-
tion reaction mixture were optimized for each primer pair. The
samples were denatured at 94°C for 5 min. PCR amplification
(35-45 cycles) was then carried out using cycles of 1 min 15 s at
94°C (denaturation), 1 min 30 s at 50-55°C (annealing) and 2 min
at 71PC (polymerization) using a programmable thermal cycler
(PC-800; ASTEC, Fukuoka, Japan). The final polymerization step
was performed for 5 min at 71°C. The annealing temperature was
optimized for each set ofprimers. PCR-amplified product solution
(5 pl) was then mixed with 5 p1 of loading solution (95%
formamide, 20 mm EDTA, 0.05% xylene cyanol). Diluted samples
were denatured at 95°C for 5 min, then loaded on 6% non-
denaturing polyacrylamide gels (firstly on a gel containing 10%
glycerol and secondly on a gel without glycerol). Electrophoresis
5' -
GGCGGTCGTGCAGACCCGGGAGAAAGATGTCAAACGTGCGAG TFCTAACGGGAG
CCCTAGCCTGGAGCGGATGGACGCCAGGCAGGCGGATCACCCCAAGCCCTCGGCC
TGCAGGAACCTCTTCGGCCCGGTGGACCACGAAGAGTTAACCCGGGACTTGGAGA
AGCACTGCAGAGACATGGAAGAGGCGAGCCAGCGCAAGTFFAATTTCGATTTT
CAGAATCACAAACCCCTAGAGGGCAAGTACGAGTGGAAGAGGTGGAGAAGGGCA
GCT2RtCOOGAG'TTCTACAGACCCCCGCFFCCCCCCAAAGGTGCCTGCAAGGT
GCCGGCGCAGGAGAGCCAGGATGGCAGCGGGAGCCGCCCGGCGGCGCCTTTAATT
GGGGCTCCGGCTAACTCTGAGGACACGCATTTGGTGGACCCAAAGACTGATCCGT
CGGACAGCCAGACGGGGTTAGCGGAGCAATGCGCAGGAATAAGGAAGCGACCTGC
AA C C GA|GA *cO#tt"c, a catagaatgtgtttggggccttcaga
cctcacgatacctgatcttactggttgatggcaaattaaaagcttatgggg
-3'
ElA primer pairs: -
El B primer pairs: =
E1C primer pairs:
E1B' primer pairs: bold
Figure 1 Position of the specific oligonucleotide primers in exon 1 of the p27gene
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Figure 2 (A) PCR-SSCP analysis of the ElA segment of the p21 gene
(non-glycerol gel). (B) PCR-SSCP analysis of the El B segment of the p21
gene (non-glycerol gel). (C) PCR-SSCP analysis of the E1C segment of the
p21 gene (10% glycerol gel). C, control DNA sample; N, no DNA (negative
control)
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Figure 3 (A) PCR-SSCP analysis of the exon 1-A of the p27gene
(non-glycerol gel). (B) PCR-SSCP analysis of the exon 1-[B+C] of the p27
gene. Upper panel, 10% glycerol gel; lower panel, non-glycerol gel. Two
patterns of migrating bands were detected. The arrows indicate a shifted
band. (C) PCR-SSCP analysis of the exon 1-C of the p27gene (non-glycerol
gel). (D) PCR-SSCP analysis of the exon E2 of the p27gene (10% glycerol
gel). C, control DNA sample; N, no DNA (negative control)
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was performed both at room temperature and 4°C (cold room) at a
constant power of 2-13 W for 6-16 h. Autoradiography was
carried out for 5-48 h without an intensifying screen.
DNA sequencing analysis
The amplified genomic DNA or cDNA fragments used for direct
sequencing were purified using Microspin Columns (Pharmacia
Biotech). Genomic DNA or cDNA fragments were sequenced in
both sense and antisense directions using an ALFred DNA
Sequencer (Pharmacia Biotech).
RESULTS
SSCP of the p21 gene
The cDNA of thep2] gene was divided into segments 1, 2 and 3.
No shifted bands were detected in segment 1, 2 or 3 (Figure 2),
suggesting that neither point mutations nor polymorphisms were
present.
SSCP of the p27gene
The coding region ofthep27gene consists oftwo exons (1 and 2).
Exon 1 was divided into three segments (1-A, 1-B and 1-C) for
detection ofmutations by PCR-SSCP. No band shifts were detected
in segments exon 1-A, exon 1-C orin exon 2 (Figure 3A, C and D).
However, three specimens (case 2, 24 and26) showedband shifting
in exon 1-B and exon 1-[B+C] (Figure 3B). Sequence analysis of
these three specimens showed no mutation or polymorphism.
DISCUSSION
Analysis of 28 specimens of human pituitary tumour found no
mutations in the coding region of thep27 gene. We also found no
mutation of the coding region ofp21. Although p27 protein has
homology to the p21 protein and is thought to belong to the prod-
ucts of the same gene family (Polyak et al, 1994; Toyoshima and
Hunter, 1994); mice lackingp21 do not develop pituitary tumours
(Deng et al, 1995). An inverse relationship between p16 and pRb
inactivation has been found in tumours such as lung cancer and
malignant glioma (Hu et al, 1994; Ueki et al, 1996), which
suggests a common regulatory mechanism for pl6 and Rb func-
tions. Recent p16 gene analysis found no abnormality in 25
specimens of human pituitary adenoma (Woloschak et al,
1996). Therefore, no abnormalities in the p16, p21 or p27 genes,
which regulate cell proliferation by suppressing hyperphosphoryl-
ation and functional inactivation of pRb, are present in human
pituitary adenomas.
The embryological morphogenesis of the intermediate lobe of
the pituitary gland is unique foreach species, but thatofthe mouse
is very similar to that of humans [Ikeda et al, 1988; Ikeda and
Yoshimoto, 1991]. Pituitary tumours arising from the intermediate
lobe are frequently observed in mice with germline mutation ofthe
p27 gene. Therefore, a similar gene abnormality may occur in
human pituitary tumours. Reduced levels of p16 protein and
mRNA have been detected in human pituitary tumours, although
nop16 gene mutation or gene loss was found. This altered expres-
sion of thep16 gene products occurs at a high frequency in human
pituitary adenoma (Woloschak et al, 1996) and is due to gene
methylation, which interferes with transcription ofthe gene.
No somatic mutations of the p21 gene were found in 158
patients with brain tumour (Koopman et al, 1995), and no muta-
tion of this gene was found in 351 DNA specimens from various
kinds of malignancies (Shirohara, 1994). Thus, we can speculate
that p2] gene mutations are not involved in the formation of
human tumours (Koopman et al, 1995). No mutations of the p27
gene were found in seven patients with leukaemias (Pietenpol et
al, 1995), in more than 20 patients with chronic lymphocytic
leukaemia (Bullrich et al, 1995) and in 147 patients with various
kinds of malignant solid tumours [Ponce-Castaneda et al, 1995].
However, p27 acts as a stoichiomeric inhibitor ofG, cyclin-CDKs
and even modest changes in the relative levels ofp27 can have a
major effect on G1 progression (Kato et al, 1994). According to
Hengst and Reed (1996), as variation in the amount ofp27 protein
occurred, the cell cycle function of p27 was regulated at the level
of protein accumulation by post-transcriptional mechanisms,
whereas the abundance of the p27 messenger RNA remained
unchanged. These findings suggest that further work is required to
clarify other mechanisms, such as transcriptional or translational
defects, that inactivate the p27 gene and other genes that cause
underphosphorylation ofpRb.
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